APP Grand Island plant gets warning letter
FDA concluded an inspection at the facility in July 2011, to which the company responded detailing the corrective and preventative actions planned to address the Agency’s concerns. In
Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular diseases.
The CSL Behring rFVIII, called rVIII-SingleChain, is being studied for the treatment of hemophilia A. The open-label, multicenter trial examines the crossover safety, efficacy and pharmacokinetics of recombinant